Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase.
Authors:
- M YoshidaMYM Yoshida
- K SugitaKSK Sugita
- S HorinouchiSHS Horinouchi
- T BeppuTBT Beppu
Open Access
- 1 October 1993
- journal article
- research article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 268 (30) , 22429-22435
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- A Novel Tetracyclic Peptide, Trapoxin, Induces Phenotypic Change from Transformed to Normal in sis‐Oncogene‐transformed NIH3T3 CellsJapanese Journal of Cancer Research, 1992
- Scaffold-attached regions (SAR elements) mediate transcriptional effects due to butyrateBiochemistry, 1992
- Yeast histone H4 N-terminal sequence is required for promoter activation in vivoCell, 1991
- Alternative chromatin structure at CpG islandsCell, 1990
- Genetic Analysis of Histone H4: Essential Role of Lysines Subject to Reversible AcetylationScience, 1990
- Affinity chromatographic purification of nucleosomes containing transcriptionally active DNA sequencesJournal of Molecular Biology, 1987
- Formation of proliferative tetraploid cells after treatment of diploid cells with sodium butyrate in rat 3Y1 fibroblastsJournal of Cellular Physiology, 1985
- Induction of teratocarcinoma cell differentiationExperimental Cell Research, 1983
- Butyrate and related inhibitors of histone deacetylation block the induction of egg white genes by steroid hormonesCell, 1980
- n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cellsNature, 1977